Elevation Point Wealth Partners LLC Has $1.03 Million Holdings in IQVIA Holdings Inc. $IQV

Elevation Point Wealth Partners LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 488.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 6,062 shares of the medical research company’s stock after purchasing an additional 5,032 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in IQVIA were worth $1,034,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. WINTON GROUP Ltd bought a new position in IQVIA in the 3rd quarter valued at about $3,383,000. J. Safra Sarasin Holding AG boosted its holdings in shares of IQVIA by 174.3% during the fourth quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock worth $2,891,000 after acquiring an additional 8,151 shares during the period. CWM LLC grew its position in shares of IQVIA by 23.9% in the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after purchasing an additional 10,762 shares during the last quarter. HF Advisory Group LLC increased its stake in shares of IQVIA by 1,791.6% during the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock worth $34,852,000 after purchasing an additional 146,444 shares during the period. Finally, Calamos Advisors LLC lifted its holdings in IQVIA by 268.1% during the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. HSBC reaffirmed a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday. Evercore reissued an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $223.88.

IQVIA Stock Down 0.5%

Shares of IQV opened at $206.07 on Tuesday. The firm has a 50 day simple moving average of $177.86 and a two-hundred day simple moving average of $188.95. The company has a market cap of $34.39 billion, a P/E ratio of 25.54, a P/E/G ratio of 1.78 and a beta of 1.20. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its board has authorized a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.